Comstock Capital Value Fund on Apogee Therapeutics Inc.
Thesis
AbbVie agreed to acquire Apogee Therapeutics for $135.11 per share in cash. The transaction values the biotechnology company at approximately $10 billion. The position is an event-driven investment expected to close in the third quarter of 2026, subject to shareholder and regulatory approvals.
“The transaction is subject to shareholder, as well as regulatory approvals and is expected to close in the third quarter of 2026.”
Key risks
- The announced acquisition may not be completed
- Regulatory approvals may delay closing